Dermatology company based in Philadelphia and Phoenix (US) which recently secured FDA approval for its product Sofdr (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used ...
EyePoint Pharmaceuticals Inc, formerly pSivida Corp develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has entered into a definitive agreement to ...
Manufacture and commercially distribute its prescription pharmaceutical SCENESSE in the European Union and the USA for the treatment of the rare, genetic metabolic disorder EPP, research and ...
Trump told reporters on Tuesday that sectoral tariffs on pharmaceuticals and semiconductor chips would also start at "25 per cent or higher, and it will go very substantially higher over the ...
We would like to use cookies to collect information about how you use ons.gov.uk. We use this information to make the website work as well as possible and improve our services.
We would like to use cookies to collect information about how you use ons.gov.uk. We use this information to make the website work as well as possible and improve our services.
Trump told reporters at his Mar-a-Lago estate in Florida on Tuesday that sectoral tariffs on pharmaceuticals and semiconductor chips would also start at "25% or higher", rising substantially over ...
Compared to 2023, the value of exports was up 14%, Ireland’s Central Statistics Office (CSO) said on Monday. Exports of medical and pharmaceutical products, meanwhile, rose by 29% to €99.9bn.
In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other stocks. The stock market may have registered losses on Friday ...
The price of West Pharmaceutical Services plunged over 38% after it released its Q4 and FY 2024 earnings results on February 13. Shareholders, mostly institutional investors apparently ...